Form D · Biotechnology
CellAge Ltd
Glasgow, X0 · CIK 0001703768
Offering snapshot reported Apr 13, 2017 · SEC filing
- Reported sold
- $25.1K Offering amount: $25.1K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $6.27K Reported outside-investor minimum
- First sale
- Mar 31, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 13, 2017 | Initial | $25,065 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-284690
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Noone will be paid compensation | None |
Source: Form D, filed Apr 13, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mantas Matjusaitis | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
272 Bath Street
Glasgow, X0, G2 4JR
Glasgow, X0, G2 4JR